Affiliations: [a] Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China | [b] Clinical Pharmacology Center, Research Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin, China | [c] Research Center for Drug Metabolism, Jilin University, Changchun, Jilin, China
Correspondence:
[*]
Corresponding author: Wei Li, Jiuwei Cui, Cancer Center of First Hospital of JiLin University, Changchun 130021, Jilin, China. Fax: +86 0430 88786134; E-mail:jdyylw@163.com; Cuijiuwei@vip.qq.com
Abstract:
BACKGROUND: The association between vitamin D levels and lung
cancer risk varies among distinct demographic populations; however, whether
vitamin D levels are related to the risk of lung cancer in Chinese
population is unknown. OBJECTIVE: We aimed to elucidate the association of plasma
25-hydroxyvitamin D [25(OH)D] level with the risk of non-small cell lung
cancer (NSCLC) in a Chinese population. METHODS: A total of 100 NSCLC patients and, 100 age-, gender-,
blood-collection-season- and resident area-matched, cancer-free controls
were recruited. Plasma 25(OH)D2 and 25(OH)D3 levels were measured by
LC/MS/MS mass spectrometry and HPLC. A logistic regression model was applied
to estimate the association between 25(OH)D concentrations and NSCLC risk. RESULTS: Multivariable analysis showed that smoking history, and
25(OH)D deficiency (< 20 ng/mL) were related to a higher risk of NSCLC
(P= 0.03). In addition, late stage (stage IIIB-IV) NSCLC was associated with
lower 25(OH)D levels, as indicated by univariate analysis. Similarly,
multivariate analysis showed that late stage (IIIB-IV) NSCLC was related to
25(OH)D deficiency. CONCLUSIONS: Plasma 25(OH)D deficiency is significantly associated
with a higher risk of NSCLC, specifically late stage NSCLC.
Keywords: 25-hydroxyvitamin D, lung cancer, non-small cell lung cancer
